ATS 2019 Virtual Final Program

323 Airway Epithelial Cells from Patients with Asthma and COPD Exhibit Improved Resistance to Rhinovirus Infection Following Treatment with TLR2 Immune Modulators/ N.W. Bartlett, S.-L. Loo, J. Girkin, D.C. Jackson, F. Mercuri, C. Demaison, Newcastle, Australia, p.A7456 BEHAVIORAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION D22 REAL WORLD MEDICATION USE IN PULMONARY DISEASES 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Trinity Ballroom 5-7 (Level 3) Abstract Summaries 9:15-9:45 Viewing/Discussion 9:45-11:15 Chairing: T. Bryant-Stephens, MD, Philadelphia, PA J. Foster, BSc(Hons), PhD, Sydney, Australia S.O. Okelo, PhD, MD, Los Angeles, CA 1001 Association of Medication Adherence and Patient Reported Outcomes in Sarcoidosis/ M. Sharp, T. Brown, D.R. Moller, C.S. Rand, K.A. Riekert, M. Eakin, Baltimore, MD, p.A5919 1002 Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib Among Commercially-Insured Adults in the United States/ T.M. Dempsey, L.R. Sangaralingham, X. Yao, A.H. Limper, Rochester, MN, p.A5920 1003 A Real-World Health Insurance Claims Analysis of Oral Prostacyclin Class Therapy Utilization and Outcomes/ D. Stafkey-Mailey, V. Saundankar, B.B. Dean, P. Classi, K. Gordon, N. Abigail, A. Nelsen, R.H. Anguiano, Palm Harbor, FL, p.A5921 1004 Real-World Prescribing Patterns of Initial Oral and Inhaled Medications Among Asthma Patients in South Korea/ N. Choi, S. Shantakumar, M.-S. Kim, C.-H. Lee, W.Y. Cheng, P. Bobbili, B.R. Yang, J. Lee, D. Hinds, M.S. Duh, H. Park, Seoul, Korea, Republic of, p.A5922 1005 Quantifying Symptomatic Patients’ Preferences for Maintenance Inhaler Therapies: Discrete Choice Experiment/ F.J. Martinez, T. Tervonen, N. Hawken, I. Gilbert, S. Heidenreich, N.A. Hanania, New York, NY, p.A5923 1006 Real-World Patterns and Implications of Short-Acting Beta-Agonist Use Among Adolescent and Adult Patients with Asthma/ N. Lugogo, I. Gilbert, N. Goshi, H. Gandhi, L. Moore-Schiltz, J. Tkacz, M. Lanz, Ann Arbor, MI, p.A5924 1007 Use of Long-Acting Muscarinic Antagonists and Biologic Therapy as Add-On Treatment for Asthma: Real-World Data Analysis Using Insurance Claims from 2012-2017/ H. Chen, Y. Ding, C. Spain, South San Francisco, CA, p.A5925 1008 Eligibility for Newer Biologic Therapies in Severe Asthma, Re-analysis of the Identification and Description of Severe Asthma patients in a cross-sectionaL (IDEAL) Study/ D. Hinds, D. Gibbons, N.B. Gunsoy, M. Stott-Miller, F.C. Albers, Collegeville, PA, p.A5926 1009 Real World Impact of Mepolizumab on Asthma Exacerbations: Adherence Matters/ B. Hahn, H. Ortega, C. Bell, M. Bogart, E. Packnett, J. Manjelievskaia, J. Llanos Ackert, Research Triangle Park, NC, p.A5927 1010 Patient and Physician Preferences for Attributes of Biologic Medications for Severe Asthma/ H. Gelhorn, Z. Balantac, C.S. Ambrose, Y. Chung, B. Stone, Bethesda, MD, p.A5928 1011 Controller Adherence and Albuterol Use Among Adult Patients with Asthma on Once or Twice Daily Ics/laba Therapy Using Clip-on Sensor Technology to Assess Outcomes/ R.H. Stanford, C.M. Averell, P. Johnson, E. Buysman, M. Carlyle, Research Triangle Park, NC, p.A5929 1012 Adherence and Asthma Control in Patients Using FF/VI with and Without a Clip-On Sensor That Monitors Adherence/ R.H. Stanford, C.M. Averell, P. Johnson, E. Buysman, M. Carlyle, Research Triangle Park, NC, p.A5930 1013 Digitally Recorded Controller and Rescue Medication Use Vary by Age in Patients with Asthma/ H. Hoch, W.C. Anderson, R. Gondalia, L. Kaye, S.J. Szefler, D.A. Stempel, Aurora, CO, p.A5931 1014 The Association of Digitally Collected Short-Acting Beta-Agonist and Maintenance Medication Use and COPD Assessment Test/ R. Gondalia, B. Theye, D.A. Stempel, San Francisco, CA, p.A5932 1015 Real-life Patterns of Short-Acting Beta-Agonist Use in Patients with COPD Vary by Time of Day and Season/ W.C. Anderson, H.E. Hoch, R. Gondalia, L. Kaye, S.J. Szefler, D.A. Stempel, Aurora, CO, p.A5933 1016 Trends in the Use of Reliever Medication by Severe Asthma Patients Treated by Allergists and Pulmonologists/ A. Kyle, K. Hanarz, S. Brown, London, United Kingdom, p.A5934 1017 Patient Decision-Making Around Use of Reliever Inhalers in Mild Asthma/ H.K. Reddel, J. Correll, J. Foster, N. Karlsson, M. Martin, C. Keen, Sydney, Australia, p.A5935 1018 A Qualitative Analysis of Factors Influencing Antibiotic Prescribing in Patients Hospitalized with an Asthma Exacerbation; the Role of Diagnostic Uncertainty/ M.S. Stefan, K.A. Spitzer, S. Zulfiqar, M. Moran, P.K. Lindenauer, Springfield, MA, p.A5936 1019 A Digital Therapy for Reducing Exacerbations and Improving Health Outcomes in Persistent Asthmatics/ S. Swaminathan, A.N. Gerber, K. Qirko, N. Wysham, E.E. Corcoran, Crestwood, KY, p.A5937 1020 Benefit of Collaborative Intervention by Physician and Community Pharmacist on Inhaler Technique/ R. Baba, K. Masaki, T. Amagai, R. Ohno, K. Fukunaga, I. Nakachi, Tochigi, Japan, p.A5938 1021 AdheRence to Inhaled Corticosteroids in Asthma (ARICA): Intervention Development/ I. Riley, R.A. Pleasants, D. Crabtree, S. Riebel, L. Svetkey, L.G. Que, M. Handley, A. Cattamanchi, H. Bosworth, L.E. Boulware, Durham, NC, p.A5939 1022 Qualitative Research on Patient Experiences of As-Needed Budesonide/Formoterol for Treatment of Mild Asthma/ J. Foster, R.W. Beasley, T. Harrison, M. Holliday, I.D. Pavord, H.K. Reddel, Sydney, Australia, p.A7457 ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 323 WEDNESDAY MORNING